Project Grant R01CA296584
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded $1,008,660 to Aim Medical Robotics Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a commercial-grade MRI-compatible neurosurgical robotic system for minimally invasive laser interstitial thermal therapy (LITT) treatment of brain tumors. Aim Medical Robotics is refining and validating the AIM Robotic System, a compact robotic platform designed to complete the full LITT workflow...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute awarded Georgia TECH Research Corp $396,457 on July 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop synergistic blood-brain barrier delivery and selective treatment of malignant glioma using pulsed field ablation and indoximod. The project investigates H-FIRE (histotripsy for focal ablation by resonant expansion), a minimally invasive focal ablation technique utilizing low-energy, microsecond-long electric pulses to induce...
- The National Cancer Institute awarded Northeastern University $224,400 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop a direct RNA sequencing platform that detects dihydrouridine (D) modifications in human lung cancer transcripts at transcriptome-wide, single-nucleotide resolution. Current technologies cannot reliably distinguish dihydrouridine from pseudouridine and uridine, limiting understanding of how uridine modifications regulate RNA biology in...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded the University of Maryland, College Park $663,736 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a multimodal KeyScope laparoscope that increases access to laparoscopic surgery in underserved settings. The project addresses the gap between the clinical standard of laparoscopic surgery—which reduces post-surgical mortality and morbidity compared to open surgery—and its limited availability in rural...
- The National Cancer Institute awarded Oregon Health & Science University $640,113 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop multifunctional ultrasound-responsive nanoparticles (URNs) for improved immunotherapy of melanoma. The project addresses the challenge that approximately 50 percent of melanoma patients do not respond to immune checkpoint inhibitor therapies due to immunosuppressive tumor microenvironments. The funded work...
- The National Cancer Institute awarded the President and Fellows of Harvard College $604,102 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop bioprinted three-dimensional vascular cancer models that enable study of T cell trafficking, dendritic cell engagement, and tumor cell killing within human and murine tumor microenvironments. The recipient will use microporous embedded printing to fabricate in vitro models incorporating vascular conduits for...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Case Western Reserve University $630,108 on March 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The recipient will develop and evaluate theranostic approaches to breast cancer using a combined fluorescence image-guided surgery and photothermal therapy platform centered on AKRO-6QC, a molecule designed for specific binding and activation by cysteine proteases...
- The National Cancer Institute awarded the University of Texas at Arlington $565,569 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for the design and synthesis of light-responsive osmium compounds to enable optical image-guided surgery and phototherapy in cancer treatment. The project will develop osmium compounds that luminesce at near-infrared wavelengths where tissue is most transparent, with the compounds engineered to be nontoxic to healthy tissue...